Technology background
Defects or chromosomal abnormalities are involved in the origin of various diseases, hereditary or non, which conventional medicine is limited to treating , using therapies to alleviate the symptoms. Recently, gene therapy arose, which consists in the insertion of a functional gene in order to correct a dysfunction or promoting new cell functions. However, despite promising, gene therapy faces several limitations relating to the penetration capability and intracellular stability of the nucleic acid used to reach the cell nucleus and edit the genome. In order to overcome these difficulties, some strategies have been used.
Technology description
The technology describes the production by high pressure homogenization of five different nanocarriers to be complexed with at least one nucleic acid made from biocompatible biomaterials, biodegradable and bioabsorbable.
Advantages
– Nanocarriers more secure and stable;
– Production scheduling possibility for the industry;
– Easier penetration into the cell membrane.
Applications
– Greater efficiency in platforms used for genome editing in gene therapy;
– Pharmaceutical / medical industry.
Nível de Maturidade da Tecnologia (TRL – Technology Readiness Level)
Status of the technology
Patent filled by INPI.
Partnership Opportunities
Licensing
Strategic partnership
Fund-raising
Inventors
Roselena Silvestri Schuh
Helder Ferreira Teixeira
Guilherme Baldo
Ursula da Silveira Matte
Talita Giacomet de Carvalho
Visit our labs (click in the logo)
